<DOC>
	<DOCNO>NCT00348816</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel prednisone , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Docetaxel may make tumor cell sensitive radiation therapy . Giving docetaxel together radiation therapy prednisone surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well give docetaxel together radiation therapy prednisone work treat patient undergone surgery prostate cancer .</brief_summary>
	<brief_title>Docetaxel , Radiation Therapy , Prednisone Treating Patients Who Have Undergone Surgery For Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine rate prostate-specific antigen ( PSA ) decline number patient reach PSA nadir zero treatment chemoradiotherapy comprise docetaxel external-beam radiotherapy follow docetaxel prednisone patient hormone-naive prostate cancer persistent rise PSA radical prostatectomy . Secondary - Determine tolerability regimen patient . - Determine progression-free survival , base PSA progression , patient . - Determine overall survival patient treat chemoradiotherapy rise PSA radical prostatectomy . - Determine velocity subsequent PSA failure impact survival patient . Tertiary - Document subsequent therapy patient whose previous treatment fail response therapy . Quaternary : To collect data contemporary cohort study receive radiation alone . We match cancer patient characteristic determine variable chemotherapy impact outcome . OUTLINE : Patients receive docetaxel IV 1 hour day 1 , 8 , 15 , 22 , 29 , 36 , 43 undergo external-beam radiotherapy day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-40 , 43-47 . Beginning within 6 week completion chemoradiotherapy , patient receive docetaxel IV 1 hour day 1 oral prednisone twice daily day 1-21 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 1 month , every 4 month 2 year , every 6 month 3 year . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Histologically confirm prostate cancer Prostatespecific antigen ( PSA ) level &gt; 0.2 ng/mL radical prostatectomy perform ≥ 6 week ago No lymph nodepositive prostate cancer No document metastatic disease CT scan abdomen pelvis negative ( within past 6 month ) No bone pain OR negative bone scan ( within past 6 month ) ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Bilirubin normal ALT AST ≤ 1.5 time upper limit normal Alkaline phosphatase normal Fertile patient must use effective contraception No peripheral neuropathy &gt; grade 1 No malignancy within last 5 year could affect diagnosis assessment prostate cancer No serious illness life expectancy &lt; 5 year No concurrent medical , psychological , social circumstance would preclude study compliance No history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No prior orchiectomy No prior chemotherapy regimen disease No prior pelvic radiotherapy No pre postoperative androgen manipulation , luteinizing hormonereleasing hormone agonist , antiandrogens ( flutamide , bicalutamide , nilutamide ) , finasteride Preoperative androgen manipulation duration ≤ 3 month allow No prior immunotherapy No prior strontium chloride Sr 89 , samarium Sm 153 lexidronam pentasodium , systemic radioisotopes No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) No concurrent herbal alternative regimen include , limited , follow : Saw palmetto PCSPES Shark cartilage No concurrent investigational agent No concurrent chemotherapy , immunotherapy , hormonal therapy ( except replacement steroid )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>